Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the latest kidney cancer clinical trial updates from the 2025 European Society for Medical Oncology (ESMO) conference in this comprehensive medical education video. Discover key findings from three major clinical trials that are shaping kidney cancer treatment approaches. Explore the RAMPART trial results showing how adjuvant Durvalumab plus Tremelimimab improved disease-free survival in intermediate-to-high risk resected renal cell carcinoma patients compared to surveillance alone. Examine the KEYMAKER-U03 trial data demonstrating the promising combination of Lenvatinib, Pembrolizumab, and Belzutifan as first-line treatment for clear cell renal cell carcinoma, with robust overall response rates and progression-free survival benefits. Review the LenCAB trial outcomes revealing how Lenvatinib plus Everolimus outperformed cabozantinib in second-line treatment of refractory clear cell renal cell carcinoma. Gain insights into these practice-changing developments in genitourinary oncology that will inform clinical decision-making for kidney cancer patients across different treatment settings and risk categories.
